Katmai Pharmaceuticals Inc.
1 clinical trials · Sponsor
◉ Watch Katmai Pharmaceuticals Inc.
| Record | Firm | Date |
|---|---|---|
| A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1) (NCT05222802) | Katmai Pharmaceuticals Inc. | 2022-02-25 |
Track Katmai Pharmaceuticals Inc. automatically
Every clearance here is in the API, with alerts when new ones post.